1. Han S, Choi HY, Kim YH, Nam JY, Kim B, Song GS, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2019 oct;50(7):751–9.
2. Chait MM, Mermelstein J, Mermelstein AC. Tegoprazan to treat gastroesophageal reflux disease. Drugs of Today. 2020;56(11):715.
3. Han S, Choi HY, Kim YH, Choi S, Kim S, Nam JY, et al. Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study. Gut Liver. 2022 nov 1;
4. Yang E, Kim S, Kim B, Kim B, Kim Y, Park SS, et al. Night‐time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. Br J Clin Pharmacol. 2022 jul 23;88(7):3288–96.
5. Han S, Choi HY, Kim YH, Nam JY, Kim B, Song GS, et al. Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of Tegoprazan. Clin Ther. 2021 ago;43(8):1371–80.